These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 1277169)

  • 1. Prophylaxis of early preneoplastic lesions of the mammary gland.
    Welsch CW
    Cancer Res; 1976 Jul; 36(7 PT 2):2621-5. PubMed ID: 1277169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of estrogen and prolactin in spontaneous mammary tumorigenesis of the mouse.
    Welsch CW
    J Toxicol Environ Health Suppl; 1976; 1():161-75. PubMed ID: 1036505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolactin and the development and progression of early neoplastic mammary gland lesions.
    Welsch CW
    Cancer Res; 1978 Nov; 38(11 Pt 2):4054-8. PubMed ID: 698954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of mammary tumorigenesis in C3H/He mice by ovariectomy or treatment with 2-bromo-alpha-ergocryptine: a comparison.
    Welsch CW; Lambrecht LK; Hassett CC
    J Natl Cancer Inst; 1977 Apr; 58(4):1135-8. PubMed ID: 576623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Suppression of mammary hyperplastic nodule formation and pituitary prolactin secretion in mice induced by ergocornine or 2-bromo-a-ergocryptine.
    Yanai R; Nagasawa H
    J Natl Cancer Inst; 1970 Dec; 45(6):1105-12. PubMed ID: 5530649
    [No Abstract]   [Full Text] [Related]  

  • 6. Synergistic effect of chronic prolactin suppression and retinoid treatment in the prophylaxis of N-methyl-N-nitrosourea-induced mammary tumorigenesis in female Sprague-Dawley rats.
    Welsch CW; Brown CK; Goodrich-Smith M; Chiusano J; Moon RC
    Cancer Res; 1980 Sep; 40(9):3095-8. PubMed ID: 6893571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prophylaxis of spontaneously developing mammary carcinoma in C3H-HeJ female mice by suppression of prolactin.
    Welsch CW; Gribler C
    Cancer Res; 1973 Nov; 33(11):2939-46. PubMed ID: 4795906
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of mammary tumorigenesis in carcinogen-treated Lewis rats by suppression of prolactin secretion.
    Welsch CW; Brown CK; Goodrich-Smith M; Van J; Denenberg B; Anderson TM; Brooks CL
    J Natl Cancer Inst; 1979 Nov; 63(5):1211-4. PubMed ID: 116049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effects of a series of prolactin inhibitors, 17beta-estradiol and 2alpha-methyldihydrotestosterone propionate, on growth of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinomas.
    Teller MN; Stock CC; Hellman L; Mountain IM; Bowie M; Rosenberg BJ; Boyar RM; Budinger JM
    Cancer Res; 1977 Nov; 37(11):3932-8. PubMed ID: 409489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 17beta-oestradiol and Enovid mammary tumorigenesis in C3H/HeJ female mice: counteraction by concurrent 2-bromo-alpha-ergocryptine.
    Welsch CW; Adams C; Lambrecht LK; Hassett CC; Brooks CL
    Br J Cancer; 1977 Mar; 35(3):322-8. PubMed ID: 576837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suppression by kampo medicines in preneoplastic mammary hyperplastic alveolar nodules of SHN virgin mice.
    Sakamoto S; Muroi N; Matsuda M; Tajima M; Kudo H; Kasahara N; Suzuki S; Sugiura Y; Kuwa K; Namiki H
    Planta Med; 1993 Oct; 59(5):425-7. PubMed ID: 8255936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylaxis of spontaneous mammary tumorigenesis by temporal inhibition of prolactin secretion in rats at young ages.
    Nagasawa H; Morii S
    Cancer Res; 1981 May; 41(5):1935-7. PubMed ID: 7214361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term cyclophosphamide treatments against primary mammary tumors in C3H/He mice.
    Costanza ME; Vaage J
    J Natl Cancer Inst; 1983 Mar; 70(3):511-6. PubMed ID: 6572739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 6-Methyl-8-beta-ergoline-acetonitrile (MEA)-induced suppression of mammary tumorigenesis in C3H/HeJ female mice.
    Welsch CW; Gribler C; Clemens JA
    Eur J Cancer (1965); 1974 Sep; 10(9):595-600. PubMed ID: 4477735
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of ovariectomy at different ages on development of mammary tumors in (C3H x R3)F1 mice.
    Richardson FL
    J Natl Cancer Inst; 1967 Aug; 39(2):347-54. PubMed ID: 18623949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in uterine morphology which accompany the development of preneoplastic and neoplastic mammary lesions in old mice.
    Brophy MO; Spring-Mills EJ
    Scan Electron Microsc; 1984; (Pt 1):335-42. PubMed ID: 6740234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-nitroso-N-methylurea-induced mammary tumors in the rat: role of prolactin and a prolactin-lowering drug.
    Gandilhon P; Mélançon R; Djiane J; Kelly PA
    J Natl Cancer Inst; 1983 Jan; 70(1):105-9. PubMed ID: 6296514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calories, parity, and prolactin influence mammary epithelial kinetics and differentiation and alter mouse mammary tumor risk.
    Engelman RW; Day NK; Good RA
    Cancer Res; 1993 Mar; 53(5):1188-94. PubMed ID: 8382558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of prenatal and neonatal administration of 5beta-dihydrotestosterone on normal and neoplastic mammary development in mice.
    Yanai R; Mori T; Nagasawa H
    Cancer Res; 1977 Dec; 37(12):4456-9. PubMed ID: 200350
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of tamoxifen on mammary preneoplasia: relevance to chemopreventive intervention.
    Telang NT; Bradlow HL; Osborne MP
    Cancer Detect Prev; 1994; 18(4):313-21. PubMed ID: 7982241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.